Answers are grounded in this paper and cite their sources.
Cannabis is a controversial product, and cannabis related businesses (CRB) currently are constrained at the federal level and in many states where the use of cannabis is illegal. To analyze whether these constraints and controversies affected performance, we created a portfolio containing cannabis firms and their stocks to measure growth and stock performance. We compared the performance of the cannabis industry with other similar "sin" industries. We found that despite the constraints and controversies surrounding the industry, firms in the cannabis industry have high growth rates and their stocks perform favorably compared to broad indexes and other "sin" industries. Based on some valuation metrics cannabis stocks currently are undervalued.
No takes yet. Share an insight, caveat, or question.
Turley et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: